Rhythm Pumps $100M Gained in Voucher Sale Back Into Imcivree

Rhythm Pumps $100M Gained in Voucher Sale Back Into Imcivree

282440

Rhythm Pumps $100M Gained in Voucher Sale Back Into Imcivree

In a $100 million deal, Rhythm Pharmaceuticals is selling its rare pediatric disease priority review voucher (PRV), granted by the U.S. Food and Drug Administration (FDA) with the approval of Imcivree (setmelanotide) to treat three rare genetic obesity disorders.  Imcivree recently became the first therapy approved to treat adults and children 6 and older with obesity caused by the deficiency of POMC, PCSK1, or LEPR, all genes involved in the appetite and weight-regulating melanocortin-4 receptor…

You must be logged in to read/download the full post.